We examine seven announcements which suggest that M&A strategy remains one of purchasing novel products and technologies that have regulatory approval and some market adoption.
This month’s recap highlights 510(k)s and a CE Mark announcement made from the AAOS exhibit hall floor. Learn what gained clearance in hip and knee joint replacement, spine and more.
As we look back on conversations from AAOS and the Canaccord Genuity Musculoskeletal Conference, we highlight three companies preparing to launch very different intraoperative technologies.
In our latest Ask the Experts series, we're answering this question: in complying with regulatory requirements, how and why should device companies avoid a “check-the-box” mentality, as opposed to a scientific-based approach?
ASTM and ISO, with help from orthopedic companies, are pursuing coating standards. Coatings have been used in orthopedics for decades, so why such a dialogue now? Industry insiders offer perspective.
The collaborative project between Numerate and Andre J. van Wijnen, Ph.D., Professor of Biochemistry and Molecular Biology and Orthopedic Surgery at Mayo Clinic, seeks to identify drug options for use in orthopedic implant surface coatings, including those for knees and hips.
Jerry Jurkiewicz, Chief Executive Officer of Orchid Orthopedic Solutions, explores the commercialization of orthopedic coatings, what's in development and what's in store for the future.
EU MDR planning is a classic project management activity to identify what has to be done, in what order, by whom and by when, and how progress will be monitored.